---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-019453"
form_type: "8-K"
ticker: null
cik: "0001560241"
company_name: "G1 Therapeutics, Inc."
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T02:49:13.795910+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# G1 Therapeutics Q1 2024: COSELA revenue $14.1M, net loss $10.2M, reaffirms 2024 guidance

## Summary
- Net COSELA revenue $14.1M in Q1 2024; total revenue $14.5M, up from $12.9M YoY.
- Net loss $10.2M ($0.20 per share) vs $27.6M ($0.53) in Q1 2023.
- Cash and securities $65.2M; runway into Q3 2025.
- Reaffirmed FY2024 COSELA net revenue guidance of $60-70M.
- Phase 3 PRESERVE 2 final analysis expected late Q2 2024; Phase 2 trilaciclib+ADC data at ASCO.

## SEC filing metadata
- accession: 0001628280-24-019453
- form_type: 8-K
- cik: 0001560241
- company_name: G1 Therapeutics, Inc.
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1560241/000162828024019453/0001628280-24-019453-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1560241/000162828024019453/gthx-20240501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-019453
- JSON: https://secwatch.observer/filing/0001628280-24-019453.json
- Plain text: https://secwatch.observer/filing/0001628280-24-019453.txt

## Key facts
- Earnings Releases
  G1 Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $14.1 million in net product sales of COSELA, net income net loss for the first quarter of 2024 was $10.2 million, EPS $(0.20). Guidance reaffirmed.
  - Period: first quarter ended March 31, 2024
  - Revenue: $14.1 million in net product sales of COSELA
  - Net income: net loss for the first quarter of 2024 was $10.2 million
  - EPS: $(0.20)
  - Guidance: reaffirmed
  - Result: reported results
  source text: G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights - Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1560241/000162828024019453/0001628280-24-019453-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.